Introduction: The Economics Changed
Five years ago, the pitch for cancer care in China was mostly about surgery costs — solid hospitals at half the Western price. That pitch is now obsolete, because the real story moved to the pharmacy.
Since 2019, China has approved more than ten domestically developed PD-1/PD-L1 inhibitors and used its National Reimbursement Drug List (NRDL) negotiations to crush their prices year after year. A cycle of a domestic PD-1 inhibitor that lists at roughly $300 can drop to as little as $60 after reimbursement-negotiated pricing — while the same drug class in the United States bills around $13,000 per four-week cycle for pembrolizumab.
This article is the 2026 update on what cancer treatment genuinely costs in China: drug prices with sources, treatment-episode math, and where international patients should go. For the institution-level view, our guide to top Chinese cancer hospitals covers departments and international services.
The Domestic PD-1 Revolution
The price gap isn't one drug being cheaper — it's an entire therapeutic class repriced:
| Drug | Origin | US annual cost | China annual cost |
|---|---|---|---|
| Pembrolizumab (Keytruda) | Merck (imported) | ~$150,000+ | ~$58,000 at Chinese list price |
| Sintilimab | Innovent (domestic) | Not marketed in US | ~$5,750 (NRDL) |
| Tislelizumab | BeiGene (domestic) | Marketed in US | ~$6,700 (NRDL) |
| Camrelizumab | Hengrui (domestic) | Not marketed in US | ~$5,000-8,000 (NRDL) |
Three numbers explain how this happened. First, NRDL negotiation: tislelizumab's negotiated price fell to ¥1,253.53 per 100 mg (about $174) — a fraction of earlier list prices. Second, competition: with 10+ PD-1s fighting for reimbursement slots, each negotiation round ratchets prices down. Third, volume: a peer-reviewed survey across 199 hospitals in Anhui province found domestic PD-1s stocked in roughly 4 out of 5 facilities, while most imported checkpoint inhibitors appeared in fewer than 16% — the domestic products are simply what the system runs on.
A 2025 pharmacoeconomic analysis published in Frontiers in Public Health put hard numbers on the multinational gap: pembrolizumab costs $2,517 per 100 mg in China versus $5,342 in the US — and even that Chinese figure reflects imported-brand pricing, not the domestic alternatives running $166-195 per 100 mg under NRDL.
Are the domestic drugs inferior? The clinical evidence says no meaningful difference: head-to-head real-world comparisons of sintilimab, camrelizumab and tislelizumab against pembrolizumab in non-small cell lung cancer found comparable efficacy and manageable safety profiles. Toripalimab — one of these "cheap Chinese alternatives" — has since earned FDA approval in the US, which tells you something about the quality ceiling here.
Immunotherapy Price Table: What a Cycle Really Costs
| Regimen | China (self-pay, list) | China (NRDL/reimbursed) | United States |
|---|---|---|---|
| Domestic PD-1 per cycle | $250-350 | $60-170 | n/a |
| Imported PD-1 per cycle (pembrolizumab) | ~$7,500-9,000 | reduced but still premium | ~$12,000-15,000 |
| Domestic PD-1 annual | $5,000-10,000 | lower with insurance | n/a |
| PD-1 + chemo first-line year | $20,000-40,000 total episode | — | $150,000-220,000 |
The pattern repeats across drug classes. Annual treatment costs run one-fifth to one-tenth of US levels: third-generation EGFR inhibitors (osimertinib-class) at $10,000-25,000 domestically versus $200,000+ in the US; ALK inhibitors at $15,000-30,000 versus $200,000+. For chronic-medication cancers — CML patients on BCR-ABL inhibitors, EGFR-mutant lung cancer on long-term TKI maintenance — five-year savings reach hundreds of thousands of dollars.
Targeted Therapy Costs
Targeted agents follow the same two-tier structure: imported originals at global-ish prices, domestic equivalents at fractions thereof.
- Osimertinib-class (3rd-gen EGFR TKI): domestic generics/natives $10,000-25,000/year; US originator $200,000+/year
- ALK TKIs (alectinib/lorlatinib class): domestic $15,000-30,000/year; US $200,000+
- HER2 ADCs (T-DXd class): NRDL negotiation cut Chinese pricing by 50%+ from launch; US remains $200,000+
- BTK inhibitors (zanidinib/zanubrutinib): BeiGene's zanubrutinib is itself FDA-approved — priced far lower at home than US comparators like ibrutinib at $180,000+
One honest caveat: for the newest molecules, the domestic option may not exist yet, and the imported version in China costs close to what it does elsewhere. The discount applies when a domestic competitor or NRDL deal exists — which now covers the highest-volume indications.
What a Treatment Episode Actually Costs
Drugs dominate oncology spending, but the full episode matters for planning. Using 2024-2026 public pricing data from the multinational pembrolizumab cost-effectiveness study plus standard tertiary-hospital tariffs:
| Item | China | United States |
|---|---|---|
| Oncology specialist consultation | ¥300-1,500 ($42-210) | $300-800 |
| Chemotherapy administration (per cycle, facility fee) | ~$110 | ~$324 |
| Imaging/work-up bundle | ~$56 | ~$851 |
| Lung cancer surgery (lobectomy, tier-3 public) | ¥60,000-120,000 ($8,400-16,700) | $40,000-80,000 |
| Breast cancer surgery | ¥40,000-80,000 ($5,600-11,100) | $30,000-70,000 |
| Standard chemo cycle (drugs + facility) | ¥10,000-30,000 ($1,400-4,200) | $15,000-50,000 |
| Hospital bed day | ¥200-600 ($28-84) | $2,000-4,000 |
A complete first-line immunotherapy-plus-chemotherapy year for advanced lung cancer — the scenario modeled in the Frontiers study — totals about $92,000 in China against $217,000 in the US, with identical QALY gains modeled. Swap the imported checkpoint inhibitor for a domestic one and the Chinese figure falls to $35,000-55,000.
Where to Get Treated: Three Flagship Centers
PUMCH (Peking Union Medical College Hospital) — the country's prestige referral center, with the deepest multidisciplinary tumor boards. See the PUMCH profile for international patient access.
West China Hospital, Chengdu — among the world's largest single-site hospitals, with a comprehensive cancer center and significantly lower living costs than Beijing/Shanghai. Details in the Chengdu West China profile.
Sun Yat-sen Memorial/University Cancer Center, Guangzhou — southern China's oncology powerhouse, strong in nasopharyngeal and hepatobiliary cancers. Profile: Guangzhou Sun Yat-sen.
All three run international patient services with English-capable coordinators. Pairing drug treatment with TCM supportive care for side-effect management is standard practice at integrated centers — and adds only $500-1,400 to a treatment month.
The Self-Pay Reality for International Patients
Honest framing of what you can and cannot access:
- You will not get local insurance rates. NRDL prices apply to Chinese insurance holders. Foreign self-pay patients pay list prices — still dramatically below US list prices, especially for domestic drugs.
- Domestic PD-1s remain accessible: at $250-350/cycle list price, a self-paying international patient pays roughly what an insured American pays in copays alone.
- Clinical trials are a hidden channel: China's trial density means eligible patients sometimes access next-generation agents free of charge. Worth asking at any flagship-center consultation.
- Visa logistics are solved: the visa-free options in our China entry guide allow up to 30 days per visit — workable for consultation-plus-first-cycle trips, with return visits scheduled between cycles.